Aridis Pharmaceuticals
Financial ratios & Valuation
Forward Multiples (2025 – 2025)
| 2025 | |
|---|---|
Price/Earnings ratio | 0.00 |
Price/Sales ratio | 0.00 |
Earnings per Share (EPS) | $1.47 |
Historical Multiples (2016 – 2022)
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | Median | |
|---|---|---|---|---|---|---|---|---|---|
Valuation Ratios
| |||||||||
Price/Earnings ratio | -12.17 | -4.16 | -1.57 | -1.29 | -2.53 | -0.67 | -0.72 | -0.11 | -1.43 |
Price/Sales ratio | 45.20 | 119.27 | 12.65 | 36.82 | 55.65 | N/A | N/A | 4.59 | 46.24 |
Price/Book Value ratio | 7.44 | 8.96 | 1.32 | 10.35 | -6.41 | -2.02 | -0.91 | -0.11 | 5.12 |
Price/Cash Flow ratio | -16.84 | -5.84 | -1.43 | -4.61 | -2.71 | -1.24 | -0.76 | -2.90 | -3.02 |
Price/Free Cash Flow ratio | -16.79 | -5.61 | -1.39 | -4.51 | -2.67 | -1.22 | -0.75 | -4.81 | -3.59 |
Price/Earnings Growth ratio | N/A | -0.02 | -0.01 | 0.02 | 0.08 | -0.01 | 0.01 | -0.00 | 0.05 |
Dividend Yield | N/A | N/A | 3.88% | N/A | N/A | 14.41% | N/A | N/A | N/A |
Profitability Indicator Ratios
| |||||||||
Gross Profit Margin | 15.07% | 100% | 100% | 100% | 100% | N/A | N/A | 66.12% | 100% |
Operating Profit Margin | -347.46% | -2295.11% | -874.75% | -2846.08% | -2240.1% | N/A | N/A | -3775.17% | -2543.09% |
Pretax Profit Margin | -371.17% | -2866.97% | -801.77% | -2904.20% | -2233.29% | N/A | N/A | -3968.79% | -2568.75% |
Net Profit Margin | -371.17% | -2866.97% | -801.77% | -2836.20% | -2191.9% | N/A | N/A | -3968.79% | -2514.05% |
Effective Tax Rate | -6.38% | -19.94% | -11.00% | 2.34% | 1.85% | 2.11% | -1.24% | N/A | 2.09% |
Return on Assets | -37.36% | -93.11% | -69.92% | -103.64% | -144.99% | -157.78% | -209.24% | -282.26% | -124.31% |
Return On Equity | -61.13% | -215.59% | -84.00% | -797.19% | 252.49% | 299.65% | 126.89% | 139.24% | -440.59% |
Return on Capital Employed | -39.14% | -84.69% | -91.65% | -336.81% | 305.89% | 667.13% | 135.08% | 107.90% | -214.23% |
Liquidity Ratios
| |||||||||
Current Ratio | N/A | N/A | 5.35 | 1.33 | 0.56 | N/A | N/A | 0.20 | 0.95 |
Quick Ratio | 9.34 | 7.98 | 5.35 | 1.46 | 0.69 | 0.81 | 0.31 | 0.05 | 1.07 |
Cash ratio | 9.29 | 7.90 | 4.57 | 1.08 | 0.36 | 0.59 | 0.13 | 0.04 | 0.72 |
Days of Sales Outstanding | 10.77 | N/A | 277.75 | 147.5 | 134.32 | N/A | N/A | 105.01 | 140.91 |
Days of Inventory outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Operating Cycle | 10.77 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Days of Payables Outstanding | 128.42 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Cash Conversion Cycle | -117.64 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Debt Ratios
| |||||||||
Debt Ratio | N/A | N/A | N/A | N/A | 0.04 | 0.22 | 0.29 | 3.95 | 1.97 |
Debt Equity Ratio | N/A | N/A | N/A | N/A | -0.08 | -0.42 | -0.17 | -1.33 | -0.04 |
Long-term Debt to Capitalization | N/A | N/A | N/A | N/A | -0.03 | -0.59 | N/A | -0.15 | -0.01 |
Total Debt to Capitalization | N/A | N/A | N/A | N/A | -0.08 | -0.73 | -0.21 | -0.64 | -0.04 |
Interest Coverage Ratio | N/A | N/A | -57.42 | N/A | N/A | N/A | N/A | -143.99 | N/A |
Cash Flow to Debt Ratio | N/A | N/A | N/A | N/A | -28.63 | -3.83 | -6.77 | -0.09 | -0.04 |
Company Equity Multiplier | 1.63 | 2.31 | 1.20 | 7.69 | -1.74 | -1.89 | -0.60 | -0.33 | 3.67 |
Cash Flow Ratios
| |||||||||
Operating Cash Flow / Sales Ratio | -2.68 | -20.41 | -8.80 | -7.98 | -20.47 | N/A | N/A | -1.58 | -8.39 |
Free Cash Flow / Operating Cash Flow Ratio | 1.00 | 1.03 | 1.02 | 1.02 | 1.01 | 1.02 | 1.00 | 0.60 | 1.01 |
Cash Flow Coverage Ratio | N/A | N/A | N/A | N/A | -28.63 | -3.83 | -6.77 | -0.09 | -0.04 |
Short Term Coverage Ratio | N/A | N/A | N/A | N/A | -46.64 | -32.95 | -6.77 | -0.14 | -0.07 |
Dividend Payout Ratio | N/A | N/A | -6.13% | N/A | N/A | -9.76% | N/A | N/A | N/A |